Drug Patents owned by Pf Prism Cv

1. List of Bosulif drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(1 year, 2 months from now)

US7767678 PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(2 years from now)

US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(2 years from now)

US11103497 PF PRISM CV Treatment of imatinib resistant leukemia
Feb, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 19, 2024

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 04 September, 2012

Treatment: A method of treating chronic myelogenous leukemia; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l

Dosage: TABLET;ORAL

How can I launch a generic of BOSULIF before it's patent expiration?
More Information on Dosage

2. List of Chantix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(8 months ago)

US7265119 PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Aug, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6890927

(Pediatric)

PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Nov, 2022

(2 months ago)

US7265119

(Pediatric)

PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Feb, 2023

(13 hours from now)

Exclusivity Exclusivity Expiration
M Feb 22, 2022
Pediatric Exclusivity (PED) Aug 22, 2022

Drugs and Companies using VARENICLINE TARTRATE ingredient

Market Authorisation Date: 10 May, 2006

Treatment: Aid to smoking cessation

Dosage: TABLET;ORAL

How can I launch a generic of CHANTIX before it's patent expiration?
More Information on Dosage

3. List of Inlyta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(2 years from now)

US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(12 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(13 years from now)

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's patent expiration?
More Information on Dosage

4. List of Pristiq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6673838 PF PRISM CV Succinate salt of O-desmethyl-venlafaxine
Mar, 2022

(11 months ago)

US8269040 PF PRISM CV Derivatives of venlafaxine and methods of preparing and using the same
Jul, 2027

(4 years from now)

Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient

Market Authorisation Date: 29 February, 2008

Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of PRISTIQ before it's patent expiration?
More Information on Dosage

5. List of Torisel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455539 PF PRISM CV CCI-779 concentrate formulations
Jul, 2023

(5 months from now)

US8299116 PF PRISM CV CCI-779 concentrate formulations
Jul, 2023

(5 months from now)

US8722700 PF PRISM CV CCI-779 formulations for parenteral administration
Jul, 2023

(5 months from now)

US8299116

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations
Jan, 2024

(11 months from now)

US8722700

(Pediatric)

PF PRISM CV CCI-779 formulations for parenteral administration
Jan, 2024

(11 months from now)

US8455539

(Pediatric)

PF PRISM CV CCI-779 concentrate formulations
Jan, 2024

(11 months from now)

US8026276 PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant
Jan, 2026

(2 years from now)

US8026276

(Pediatric)

PF PRISM CV Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant
Jul, 2026

(3 years from now)

US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
May, 2032

(9 years from now)

US8791097

(Pediatric)

PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
Nov, 2032

(9 years from now)

Drugs and Companies using TEMSIROLIMUS ingredient

Market Authorisation Date: 30 May, 2007

Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; Method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of TORISEL before it's patent expiration?
More Information on Dosage

6. List of Tygacil drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9694078 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(3 years from now)

US10588975 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(3 years from now)

US9254328 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(3 years from now)

US8975242 PF PRISM CV Tigecycline compositions and methods of preparation
Oct, 2028

(5 years from now)

US7879828 PF PRISM CV Tigecycline compositions and methods of preparation
Feb, 2029

(6 years from now)

US8372995 PF PRISM CV Crystalline solid forms of tigecycline and methods of preparing same
Oct, 2030

(7 years from now)

Drugs and Companies using TIGECYCLINE ingredient

Market Authorisation Date: 15 June, 2005

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

7. List of Xalkori drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785632 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Mar, 2025

(2 years from now)

US7230098 PF PRISM CV Aminoheteroaryl compounds as protein kinase inhibitors
Aug, 2025

(2 years from now)

US7858643 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Oct, 2029

(6 years from now)

US8217057 PF PRISM CV Polymorphs of a c-MET/HGFR inhibitor
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7825137 PF PRISM CV Method of treating abnormal cell growth
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 14, 2028
New Indication (I) Jul 14, 2025

Drugs and Companies using CRIZOTINIB ingredient

Market Authorisation Date: 26 August, 2011

Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; Treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive

Dosage: CAPSULE;ORAL

More Information on Dosage

8. List of Xeljanz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(a month from now)

USRE41783 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024
New Patient Population (NPP) Sep 25, 2023

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 06 November, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XELJANZ before it's patent expiration?
More Information on Dosage

9. List of Zmax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6984403 PF PRISM CV Azithromycin dosage forms with reduced side effects
Feb, 2024

(1 year, 11 days from now)

US7887844 PF PRISM CV Multiparticulate crystalline drug compositions having controlled release profiles
Feb, 2024

(1 year, 11 days from now)

Drugs and Companies using AZITHROMYCIN ingredient

Market Authorisation Date: 10 June, 2005

Treatment: Method of treating bacterial infections

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in